Fujifilm Holdings Corp. will restart a clinical trial in Japan of the company’s antiviral drug Avigan for the treatment of Covid-19, the Nikkei newspaper reported on Feb. 21.

A study of global trials of Fujifilm Holdings Corp.’s Avigan suggests the antiviral drug has little benefit for Covid-19 patients once their symptoms become serious.

BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.

Despite some controversy over the  effectiveness of Gilead Sciences’ Veklury (remdesivir) as the first antiviral drug approved to treat Covid-19, the product is bolstering the company’s bottom line and 2020 guidance was updated to reflect that.

The European Commission approved Swiss drugmaker Roche’s Xofluza to treat influenza in patients aged 12 years and older, the first new influenza antiviral for patients in almost 20 years.

The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.

Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.

A single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral drug had no impact on death rates from the disease.

Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.  

Amgen, UCB and Takeda launched a global trial to identify whether any of three different drugs can reduce the severity of Covid-19 in hospitalized patients by moderating the immune system’s response to the disease.